Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United Microelectronics Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while United Microelectronics Corp trades at $23.76 (market cap $61.20B). The key difference: United Microelectronics Corp is the larger of the two by market cap, and United Microelectronics Corp pays a 1.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UMC | |
|---|---|---|
Market Cap | $39.89B | $61.20B |
Sector | Health | Technology |
52-Week High | $491.22 | $28.02 |
52-Week Low | $278.09 | $6.58 |
Enterprise Value | $38.15B | $58.77B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
UMC trades at $24.34, down 2.09% today, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $237.55B in 2025, though net income margin compressed to 16.99%. Recent June 2026 sales rose 22.85% year-over-year, and the company launched a 14nm eHV FinFET platform for display drivers. Analyst consensus is mixed with 27% buy ratings, while institutional sentiment leans positive amid AI and automotive chip demand.
Outlook: UMC benefits from specialty semiconductor demand, but high P/E of 39.52 and margin pressures pose valuation risks. Earnings beats and dividend payments support income investors, yet competition and cyclical industry volatility require caution for growth-focused shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
